Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Actelion; Idorsia Pharmaceuticals Ltd.
• Treatments: Cetirizine

Criteria

Inclusion Criteria:

• Males and females aged 18 to 70 years.

• Clinical history of symptomatic seasonal allergic rhinitis associated with mountain cedar pollen for the last two years.

• Adequate exposure to mountain cedar pollen.

• Positive skin prick test to mountain cedar allergen within 12 months of screening.

• Sufficient nasal symptom score during a run-in period.

Exclusion Criteria:

• Non-allergic rhinitis.

• Bacterial or viral respiratory tract infection.

• Chronic respiratory disorders.

• Asthma requiring treatment other than inhaled short-acting Beta2-agonists.

• Ocular infections or surgery, nasal obstruction, nasal biopsy or surgery, sinus surgery or perforation.

• Smoking within the last year.

• Ongoing or recent treatment for seasonal allergic rhinitis.

• Initiation of allergen immunotherapy within 6 months of screening.